Craneware plc

AIM:CRW Stock Report

Market Cap: UK£812.4m

Craneware Valuation

Is CRW undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of CRW when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: CRW (£23.2) is trading above our estimate of fair value (£19.16)

Significantly Below Fair Value: CRW is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for CRW?

Key metric: As CRW is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for CRW. This is calculated by dividing CRW's market cap by their current earnings.
What is CRW's PE Ratio?
PE Ratio87x
EarningsUS$11.70m
Market CapUS$1.02b

Price to Earnings Ratio vs Peers

How does CRW's PE Ratio compare to its peers?

The above table shows the PE ratio for CRW vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average38.6x
EMIS EMIS Group
40.4x11.0%UK£1.2b
INS Instem
59.8xn/aUK£199.6m
SPI Spire Healthcare Group
31.3x26.9%UK£885.2m
CVSG CVS Group
22.8x15.5%UK£596.9m
CRW Craneware
87x24.3%UK£812.4m

Price-To-Earnings vs Peers: CRW is expensive based on its Price-To-Earnings Ratio (87x) compared to the peer average (27x).

Price to Earnings Ratio vs Industry

How does CRW's PE Ratio compare vs other companies in the European Healthcare Services Industry?

2 CompaniesPrice / EarningsEstimated GrowthMarket Cap
CRW 87.0xIndustry Avg. 18.6xNo. of Companies4PE020406080100+
2 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: CRW is expensive based on its Price-To-Earnings Ratio (87x) compared to the European Healthcare Services industry average (18.6x).

Price to Earnings Ratio vs Fair Ratio

What is CRW's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

CRW PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio87x
Fair PE Ratio35.9x

Price-To-Earnings vs Fair Ratio: CRW is expensive based on its Price-To-Earnings Ratio (87x) compared to the estimated Fair Price-To-Earnings Ratio (35.9x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst CRW forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUK£23.20
UK£28.72
+23.8%
6.4%UK£31.11UK£26.09n/a6
Nov ’25UK£19.95
UK£28.56
+43.1%
6.1%UK£30.99UK£26.01n/a6
Oct ’25UK£19.55
UK£28.49
+45.7%
4.6%UK£30.30UK£26.99n/a5
Sep ’25UK£21.50
UK£26.44
+23.0%
4.0%UK£28.08UK£24.85n/a5
Aug ’25UK£23.00
UK£27.32
+18.8%
4.0%UK£29.22UK£25.87n/a5
Jul ’25UK£23.10
UK£26.87
+16.3%
4.5%UK£29.05UK£25.41n/a5
Jun ’25UK£24.60
UK£26.75
+8.8%
4.6%UK£28.92UK£25.29n/a5
May ’25UK£22.40
UK£27.11
+21.0%
4.9%UK£29.40UK£25.71n/a5
Apr ’25UK£22.00
UK£26.85
+22.1%
4.7%UK£29.07UK£25.42n/a5
Mar ’25UK£21.10
UK£26.25
+24.4%
8.1%UK£28.68UK£22.83n/a4
Feb ’25UK£21.10
UK£24.50
+16.1%
13.5%UK£28.64UK£19.99n/a4
Jan ’25UK£17.50
UK£24.01
+37.2%
14.4%UK£28.00UK£18.88n/a4
Dec ’24UK£16.50
UK£23.63
+43.2%
17.4%UK£28.08UK£17.23n/a4
Nov ’24UK£16.20
UK£24.51
+51.3%
18.2%UK£29.69UK£18.00UK£19.954
Oct ’24UK£15.00
UK£24.39
+62.6%
18.1%UK£29.47UK£17.87UK£19.554
Sep ’24UK£13.75
UK£26.81
+95.0%
9.0%UK£29.53UK£23.65UK£21.503
Aug ’24UK£13.30
UK£25.37
+90.8%
9.4%UK£28.72UK£23.01UK£23.004
Jul ’24UK£13.65
UK£25.23
+84.8%
7.0%UK£27.80UK£22.98UK£23.104
Jun ’24UK£14.30
UK£25.81
+80.5%
8.0%UK£28.64UK£22.94UK£24.604
May ’24UK£13.50
UK£25.81
+91.2%
8.0%UK£28.64UK£22.94UK£22.404
Apr ’24UK£11.50
UK£25.81
+124.4%
8.0%UK£28.64UK£22.94UK£22.004
Mar ’24UK£14.40
UK£26.26
+82.4%
11.6%UK£31.09UK£22.95UK£21.104
Feb ’24UK£14.30
UK£26.26
+83.6%
11.6%UK£31.09UK£22.95UK£21.104
Jan ’24UK£18.15
UK£28.08
+54.7%
10.4%UK£31.20UK£24.18UK£17.503
Dec ’23UK£21.95
UK£28.08
+27.9%
10.4%UK£31.20UK£24.18UK£16.503
Nov ’23UK£18.65
UK£28.39
+52.3%
9.6%UK£31.09UK£24.67UK£16.203

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

Centene

US$30.5b

Operates as a healthcare enterprise that provides programs and services to under-insured and uninsured families, commercial organizations, and military families in the United States.

0HVB

US$60.47

7D

5.2%

1Y

-18.4%

Elevance Health

US$93.4b

Operates as a health benefits company in the United States.

0HG8

US$401.70

7D

-0.06%

1Y

-16.0%

Enovis

US$2.6b

Operates as a medical technology company focus on developing clinically differentiated solutions worldwide.

0I1B

US$46.90

7D

2.6%

1Y

-8.3%